• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

European Society for Medical Oncology (ESMO) Asia

December 06 - 08, 2024

  1. Durvalumab
  2. Durvalumab + Tremelimumab
  3. Trastuzumab Deruxtecan

ppt

Safety of 30 min infusion of durvalumab in combination with gemcitabine-based chemotherapy in first-line treatment of advanced biliary tract cancer: TOURMALINE early results

pdf

Impact of baseline tumour burden on outcomes in EMERALD-1: A phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolisation in embolisation-eligible unresectable hepatocellular carcinoma

pdf

PACIFIC-5: A phase 3 study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT),

ppt

Five-year overall survival and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

ppt

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis

pdf

Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis [Plain languagae summary]

pdf

Randomized, open-label, multicenter, Phase 3 study of trastuzumab deruxtecan and rilvegostomig vs standard of care in first-line, HER2-expressing, locally advanced or metastatic biliary tract cancer: DESTINY-BTC01

pdf

An open-label, multicenter, phase 2 study of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINY PanTumor02 part 2

pdf

A Phase 1b/2 open-label study evaluating trastuzumab deruxtecan in combination with rilvegostomig and chemotherapy in patients with HER2+ and HER2-low gastric cancers: DESTINY-Gastric03 Part 4

pdf

Real-world treatment patterns in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinomain East Asia

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No